Zafieon Insights

Perspective frominside the work.

Notes on women's health, manufacturing quality and responsible pharmaceutical practice — written from what we do, not about what the market is doing.

Latest

Novartis Signs Up to $3.2 Billion Deal with Alteogen for Drug-Delivery Technology

Novartis has entered a deal worth up to $3.2 billion with South Korea’s Alteogen to access advanced drug-delivery technology that could enable certain intravenous medicines to be developed as more convenient injectable formulations.

Women's Health
Gynaecology
Healthcare

Read

More from Zafieon

04 pieces

Manufacturing
Pharmaceutical Industry
Healthcare

cipla and Qilu Pharmaceutical Partner to Advance Keytruda Biosimilar in the U.S.

Cipla has partnered with China’s Qilu Pharmaceutical to bring QL2107, a biosimilar of Merck’s leading cancer immunotherapy Keytruda, to the U.S. market, strengthening its presence in the growing oncology and biosimilars segment.

Read

Hormonal Health
Manufacturing
Research & Development

Gland Pharma Clears USFDA Inspection with Zero Observations

Gland Pharma’s Visakhapatnam sterile oncology and API facilities successfully completed a USFDA GMP inspection with zero Form 483 observations, highlighting its strong commitment to manufacturing quality and regulatory compliance.

Read

Nutraceuticals
Women's Health
Pharma Innovation

Sun Pharma Reaches U.S. Drug-Pricing Agreement, Strengthening Global Market Access

Sun Pharmaceutical Industries has joined a new group of pharmaceutical companies agreeing to provide medicines to U.S. state Medicaid programs at Most-Favoured-Nation pricing, highlighting the evolving landscape of global drug pricing and market access.

Read

Zafieon Insights carries Zafieon Pharma's own perspective on its focus, its quality framework and its manufacturing partnerships. It is not medical advice, it does not describe any product's indications, benefits or effects, and it is not a substitute for professional medical judgement.